Compare Robinhood Markets, Inc. (HOOD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Robinhood (HOOD) trades at $101.08, down 7.45% in the last session, as investors digest mixed quarterly results. The stock shows neutral technical signals with support at $108 and resistance at $110. Fundamentally, the company demonstrates strong revenue growth from $3.0B in 2024 to $4.5B in 2025, with robust 42% net margins, though valuation multiples remain elevated with a P/E of 48.9. Recent announcements include plans for 24/7 stock trading and expanded crypto offerings.

Outlook remains positive with 77% analyst buy ratings and a $138.60 consensus price target implying 37% upside. Key opportunities include market share gains from new trading features, while risks involve high valuation sensitivity and regulatory scrutiny over leveraged crypto products. The Q3 2026 earnings report on October 27 will be critical for validating growth trajectory.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.